Washington Roundup
Will the Supreme Court Grant Cert in Myriad Patent Case?
WASHINGTON – The Supreme Court is set to consider Friday whether it wants the last word on the patentability of Myriad Genetics Inc.'s claims on the BRCA1 and BRCA2 genes, used in diagnostics for breast and ovarian cancer.